Researchers at the Universities of Edinburgh and Bristol found that a bisphosphonate medication commonly used to treat osteoporosis blocked abnormal mineral deposits in the spines of genetically altered zebrafish. The fish, bred without a functioning copy of a gene associated with collagen IX, developed spinal degeneration similar to the human condition as they aged.
The team observed that minerals accumulated in spinal tissues, causing normally flexible structures to become rigid and leading to spinal fusion, where neighboring vertebrae join together. Importantly, structural breakdown began before the mineral deposits appeared, suggesting that tissue deterioration may trigger a chain reaction of spinal damage.
Gene activity analysis revealed disturbances in fat metabolism, mTOR signaling, phosphate regulation, and vitamin A signaling. These changes suggest that spinal disc degeneration involves alterations in how cells process nutrients and regulate growth, beyond simple tissue wear.
In the zebrafish experiments, the bisphosphonate medication successfully reduced abnormal mineral buildup. Restricting food consumption and medications that suppressed fat metabolism also reduced spinal fusions, pointing to fat metabolism and phosphate regulation as potential drug targets.
Dr. Erika Kague, who led the research at the University of Edinburgh's Institute of Genetics and Cancer, stated: "For decades, surgery has been the only real answer for disc disease. By understanding the biology that drives the spine to harden, our zebrafish studies point to several ways of slowing it down, including a drug already used safely in patients."
The study appeared in Communications Biology and received support from Arthritis UK and BBSRC. The researchers note that human studies are needed to confirm whether the same biological mechanisms operate in people and whether treatments targeting these mechanisms can safely prevent or slow spinal disc degeneration.